| CAT No: | CL-CFL-01 |
| CAS No: | 153-61-7 |
| Mol.F: | C16H16N2O6S2 |
| Mol.Wt.: | 396.4 |
| Chemical Name: | (6R,7R)-3-[(Acetyloxy)methyl]-8-oxo-7-[(thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Inventory Status: | Custom synthesis |
This impurity is related to Cefalotin Sodium is provided with comprehensive characterization data in accordance with regulatory guidelines. It is suitable for use in analytical method development, method validation (AMV), Quality Control (QC) applications for Abbreviated New Drug Applications (ANDA) and commercial production of Asenapine.
Cefalotin Sodium is used as a reference standard in analytical research. It ensures consistency of formulations.
Chemical Name: (6R,7R)-3-[(Acetyloxy)methyl]-8-oxo-7-[(thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Country of Origin: India Product Category: Impurity Reference StandardAPI NAME: Cefalotin Molecular Formula: C16H16N2O6S2
Molecular Weight: 396.4
Storage: Store in a cool, dry place.
| Product Name: | Cefalotin Sodium |
| CAS No: | 153-61-7 |
| Mol.F.: | C16H16N2O6S2 |
| Mol.Wt.: | 396.4 |
Cat. No: CL-CFL-02
CAS No: 34691-02-6
Mol. F: C14H14N2O4S2
Mol. Wt: 338.4
Inv. Status: Custom Synthesis
Cat. No: CL-CFL-03
CAS No: 5935-65-9
Mol. F: C14H14N2O5S2
Mol. Wt: 354.4
Inv. Status: Custom Synthesis
Cat. No: CL-CFL-04
CAS No: 957-68-6
Mol. F: C10H12N2O5S
Mol. Wt: 272.3
Inv. Status: Custom Synthesis
Cat. No: CL-CFL-05
CAS No: 10590-10-0
Mol. F: C14H12N2O4S2
Mol. Wt: 336.4
Inv. Status: Custom Synthesis
Cat. No: CL-CFL-NO-01
CAS No: NA
Mol. F: C16H15N3O7S2
Mol. Wt: 425.43
Inv. Status: Custom Synthesis
Cat. No: CL-CFL-06
CAS No: 93808-81-2
Mol. F: C16H15ClN2O6S2
Mol. Wt: 430.9
Inv. Status: Custom Synthesis
Cat. No: CL-CFL-07
CAS No: 104758-14-7
Mol. F: C15H14N2O6S2
Mol. Wt: 382.4
Inv. Status: Custom Synthesis
Cat. No: CL-CFL-08
CAS No: 88837-50-7
Mol. F: C16H16N2O7S2
Mol. Wt: 412.4
Inv. Status: Custom Synthesis
Catalog No:
CAS No:
Mol. Formula:
Mol. Weight:
Chemical Name
Inv Status: